BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 35770869)

  • 1. Impact of probiotics use on clinical outcomes of immune checkpoint inhibitors therapy in cancer patients.
    Wan L; Wu C; Wu Q; Luo S; Liu J; Xie X
    Cancer Med; 2023 Jan; 12(2):1841-1849. PubMed ID: 35770869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating Oral Probiotic Supplements as Complementary Treatment in Advanced Lung Cancer Patients Receiving ICIs: A Prospective Real-World Study.
    Tong L; Wan Y; Shi X; Liu X; Liu Z; Li Y; Zhang Y; Luo D; Zhu J
    Cancer Control; 2024; 31():10732748241253959. PubMed ID: 38736182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non-small-cell lung cancer.
    Morita A; Ichihara E; Inoue K; Fujiwara K; Yokoyama T; Harada D; Ando C; Kano H; Oda N; Tamura T; Ochi N; Kawai H; Inoue M; Hara N; Fujimoto N; Ichikawa H; Oze I; Hotta K; Maeda Y; Kiura K
    Int J Cancer; 2024 May; 154(9):1607-1615. PubMed ID: 38196128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    Chen H; Han KD; He ZJ; Huang YS
    Technol Cancer Res Treat; 2021; 20():15330338211033498. PubMed ID: 34323149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of glucocorticoid use on survival of advanced non-small-cell lung cancer patients treated with immune checkpoint inhibitors.
    Li N; Zheng X; Gan J; Zhuo T; Li X; Yang C; Wu Y; Qin S
    Chin Med J (Engl); 2023 Nov; 136(21):2562-2572. PubMed ID: 37925595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis.
    Lopes S; Pabst L; Dory A; Klotz M; Gourieux B; Michel B; Mascaux C
    Front Immunol; 2023; 14():1070076. PubMed ID: 36776847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Value of Lymphocyte-to-Monocyte Ratio (LMR) in Cancer Patients Undergoing Immune Checkpoint Inhibitors.
    Wan L; Wu C; Luo S; Xie X
    Dis Markers; 2022; 2022():3610038. PubMed ID: 36590752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
    Ba H; Liu L; Peng Q; Chen J; Zhu YD
    BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the Relationship Between Liver Metastases and the Survival of Patients With Non-Small Cell Lung Cancer After Immune Checkpoint Inhibitors Treatment: A Systematic Review and Meta-Analysis.
    Xu H; Ming P; Zhao Z; Zhao N; Zhou D; Tang X; Cao D
    Integr Cancer Ther; 2023; 22():15347354231164584. PubMed ID: 36998207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive Efficacy of Blood-Based Tumor Mutation Burden Assay for Immune Checkpoint Inhibitors Therapy in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    Zhang N; Zhang J; Wang G; He X; Mi Y; Cao Y; Yu X
    Front Oncol; 2022; 12():795933. PubMed ID: 35223476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of antibiotics on efficacy of immune checkpoint inhibitors in malignancies: A study based on 44 cohorts.
    Wu Q; Liu J; Wu S; Xie X
    Int Immunopharmacol; 2021 Mar; 92():107303. PubMed ID: 33465728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
    Zhang N; Jiang J; Tang S; Sun G
    Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of immune checkpoint inhibitors in advanced
    Hu J; Huang D; Wang Y; Li D; Yang X; Fu Y; Du N; Zhao Y; Li X; Ma J; Hu Y
    Front Immunol; 2022; 13():975246. PubMed ID: 36159795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The landscape of immune checkpoint inhibitor therapy in advanced lung cancer.
    Wang C; Li J; Zhang Q; Wu J; Xiao Y; Song L; Gong H; Li Y
    BMC Cancer; 2021 Aug; 21(1):968. PubMed ID: 34454455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of prior fluoroquinolone treatment with survival outcomes of immune checkpoint inhibitors in Asia.
    Lu PH; Tsai TC; Chang JW; Deng ST; Cheng CY
    J Clin Pharm Ther; 2021 Apr; 46(2):408-414. PubMed ID: 33332621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
    Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
    Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of liver metastasis on the efficacy of immune checkpoint inhibitors in cancer patients: a systemic review and meta-analysis.
    Tian BW; Han CL; Wang HC; Yan LJ; Ding ZN; Liu H; Mao XC; Tian JC; Xue JS; Yang LS; Tan SY; Dong ZR; Yan YC; Wang DX; Li T
    Clin Exp Metastasis; 2023 Aug; 40(4):255-287. PubMed ID: 37308706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive impact of sarcopenia in solid cancers treated with immune checkpoint inhibitors: a meta-analysis.
    Takenaka Y; Oya R; Takemoto N; Inohara H
    J Cachexia Sarcopenia Muscle; 2021 Oct; 12(5):1122-1135. PubMed ID: 34337889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognosis stratification of cancer patients treated with immune checkpoint inhibitors through lung immune prognostic index: a meta-analysis and systematic review.
    Guo Y; Pan Y; Wan J; Gong B; Li Y; Kan X; Zheng C
    BMC Cancer; 2024 Apr; 24(1):523. PubMed ID: 38664760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.